BIOFRONTERA INC. TO PARTICIPATE IN RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES ON WEDNESDAY, NOVEMBER 30, MONDAY, DECEMBER 5, FRIDAY, DECEMBER 9, AND MONDAY, DECEMBER 19 2022
November 28 2022 - 10:05AM
Biofrontera Inc. ("Biofrontera" or the "Company") (NASDAQ: BFRI),
announced today that they will be participating in Renmark
Financial Communications Inc.’s live Virtual Non-Deal Roadshow
Series to discuss its latest investor presentation on Wednesday,
November 30, 2022, at 12:00 PM EST, Monday, December 5, 2022, at
1:00 PM CST, Friday, December 9, 2022 at 12:00 PM EST and Monday,
December 19, 2022 at 1:00 PM PST. Biofrontera Inc. welcomes
stakeholders, investors, and other individual followers to register
and attend these live events.
The presentation will feature Prof. Hermann
Luebbert, Executive Chairman, Erica Monaco, CEO, and Fred Leffler,
CFO. Topics to be covered will include the investor presentation
including the latest company news, followed by a live Q&A.
Investors interested in participating in this event will need to
register using the link below. As a reminder, registration for the
live event may be limited, but access to the replay after the event
will be on the company’s investor page.
REGISTER HERE:
Wednesday, November
30, 2022:
https://www.renmarkfinancial.com/events/renmark-virtual-non-deal-roadshow-nasdaq-bfri-2022-11-30-120000
Monday, December
5, 2022:
https://www.renmarkfinancial.com/events/renmark-virtual-non-deal-roadshow-nasdaq-bfri-2022-12-05-130000
Friday, December 9,
2022:https://www.renmarkfinancial.com/events/renmark-virtual-non-deal-roadshow-nasdaq-bfri-2022-12-09-120000
Monday, December 19, 2022:
https://www.renmarkfinancial.com/events/renmark-virtual-non-deal-roadshow-nasdaq-bfri-2022-12-19-130000
- To ensure smooth
connectivity, please access this link using the latest version of
Google Chrome.
About Biofrontera
Inc.Biofrontera is a U.S.-based biopharmaceutical company
commercializing a portfolio of pharmaceutical products focused on
the fields of photodynamic therapy and topical antibiotics. In
collaboration with healthcare providers, we are fully committed to
advancing treatment options and patient care. Biofrontera, Inc. was
founded in March 2015 to commercialize the FDA-approved flagship
drug Ameluz® (aminolevulinic acid hydrochloride) gel, 10%, in the
United States. In 2019, Biofrontera Inc. expanded its U.S.-product
portfolio with the FDA-approved drug Xepi® (ozenoxacin) cream, 1%.
With both FDA-approved products, Biofrontera Inc. is ideally
positioned for sustainable growth.
About Renmark Financial Communications
Inc.Founded in 1999, Renmark Financial Communications Inc.
is North America’s leading retail investor relations firm.
Employing a strategic and comprehensive mix of exposure tactics;
Renmark hosts Virtual Non-Deal Roadshows as well as in-person
corporate presentations and maintains daily communications with
thousands of brokers and money managers across Canada and the
United States. Renmark empowers its publicly traded clientele to
maximize their visibility within the financial community and
strengthen their investor audience.
CONTACT:Renmark Financial Communications
Inc.Robert Thaemlitz: rthaemlitz@renmarkfinancial.com
Tel.: (416) 644-2020 or (212) 812-7680www.renmarkfinancial.com
Biofrontera (NASDAQ:BFRIW)
Historical Stock Chart
From Jul 2024 to Aug 2024
Biofrontera (NASDAQ:BFRIW)
Historical Stock Chart
From Aug 2023 to Aug 2024